NCT00140907

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 367 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional therapy) will reduce the number of RT patients who experience histological lesions of chronic allograft nephropathy

Conditions

• High Blood Pressure

Interventions

Type	Name	Description
DRUG	losartan potassium	25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
DRUG	Comparator: Placebo	25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.

Timeline

• Start date: 2000-03-14
• Primary completion: 2005-01-01
• Completion: 2005-01-01
• First posted: 2005-09-01
• Last updated: 2024-08-15